How Good Is the Evidence Behind Anti-CGRP Migraine Drug Trials? | Research

The takeaway

Published clinical trials of anti-CGRP migraine drugs have notable reporting quality gaps and potential biases that readers should consider.

Reporting gaps identified
Even well-known anti-CGRP migraine trials showed notable gaps in reporting quality beyond randomization-related biases

What the researchers found

Published RCTs of anti-CGRP monoclonal antibodies for migraine have notable reporting quality gaps and potential biases beyond randomization.

Why it matters

Understanding the quality of clinical trial evidence helps doctors and patients make better-informed decisions about migraine treatments. Even well-known drugs deserve scrutiny of their evidence base.

The numbers in context

The review covered phase II/III RCTs of anti-CGRP monoclonal antibodies for both episodic and chronic migraine, found through PubMed and EMBASE.

How the study worked

Systematic review of phase II/III randomized controlled trials, assessed using PRISMA guidelines on PubMed and EMBASE databases.

Who was studied

Systematic review of phase II/III RCTs in episodic and chronic migraine patients

What this study cannot tell us

The review only assessed reporting quality and bias risk, not whether the drugs are effective. Some biases may be inherent to the trial designs used across the field.

How to read the evidence

Rated moderate: rigorous methodological assessment using established bias assessment tools, but evaluates reporting quality rather than drug effectiveness.

When this study was published

Published in 2024. Reviews the complete published trial base for anti-CGRP migraine drugs.

The bigger picture

Anti-CGRP drugs are widely prescribed based on these trials. Understanding their limitations helps doctors and patients make more nuanced decisions about treatment benefits and risks.

Questions still open

Do the reporting gaps affect the overall conclusions about drug effectiveness?
Should future CGRP trials follow stricter reporting standards?

Common questions

Are anti-CGRP migraine drug trials reliable?

They show the drugs work, but reporting gaps and biases mean the effect sizes should be interpreted with some caution.

What kind of biases were found?

Biases beyond randomization, including selective reporting and methodological limitations in how outcomes were measured and presented.

Read the original research

Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review.

Journal of clinical medicine, 13(7)

View on PubMed ↗Publisher’s paper ↗

Citation

Rikos, Dimitrios; Vikelis, Michail; Dermitzakis, Emmanouil V; Soldatos, Panagiotis; Rallis, Dimitrios; Rudolf, Jobst; Andreou, Anna P; Argyriou, Andreas A. (2024). Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review.. Journal of clinical medicine, 13(7). https://doi.org/10.3390/jcm13071964